About Voltage-dependent calcium channel gamma-4 subunit
Voltage-dependent calcium channel gamma-4 subunit (CACNG4) is a protein
from Homo sapiens identified by UniProt accession
Q9UBN1, 327 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | Voltage-dependent calcium channel gamma-4 subunit |
|---|
| UniProt accession | Q9UBN1 |
|---|
| Gene | CACNG4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 327 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (47)
Diseases linked to this target (Open Targets).
- cardiovascular disease · score 0.46
- generalized anxiety disorder · score 0.39
- Polyuria · score 0.37
- gastrointestinal disease · score 0.37
- Urinary incontinence · score 0.37
- PHF-tau measurement · score 0.28
- anxiety · score 0.27
- breast adenocarcinoma · score 0.25
- lung adenocarcinoma · score 0.21
- endometrial cancer · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UBN1-F1 | alphafold | PREDICTED | 66.21 | — |
Amino-acid sequence (327 residues)
MVRCDRGLQM LLTTAGAFAA FSLMAIAIGT DYWLYSSAHI CNGTNLTMDD GPPPRRARGD LTHSGLWRVC CIEGIYKGHC FRINHFPEDN DYDHDSSEYL LRIVRASSVF PILSTILLLL GGLCIGAGRI YSRKNNIVLS AGILFVAAGL SNIIGIIVYI SSNTGDPSDK RDEDKKNHYN YGWSFYFGAL SFIVAETVGV LAVNIYIEKN KELRFKTKRE FLKASSSSPY ARMPSYRYRR RRSRSSSRST EASPSRDVSP MGLKITGAIP MGELSMYTLS REPLKVTTAA SYSPDQEASF LQVHDFFQQD LKEGFHVSML NRRTTPV
Explore Voltage-dependent calcium channel gamma-4 subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets